Drug
Maplirpacept clinical trials
Also written TTI-622.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
8 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 2
Pfizer (6) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Carfilzomib (1) · Glofitamab (1) · Obinutuzumab (1) · Tafasitamab (1) · Lenalidomide (1) · Liposomal doxorubicin (1) · Doxorubicin (1)
Studies
Open first, then newest update. How each study uses maplirpacept is read from its arms, and is right about nine times in ten.
Testing it · 8
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple MyelomaActive, not recruitingPhase 1PfizerNCT05675449Written as Maplirpacept
- A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple MyelomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT05139225Written as TTI-622
- A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.TerminatedPhase 1/2PfizerNCT05896163Written as maplirpacept (PF-07901801)
- TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingPhase 2Mayo ClinicNCT05507541Written as Maplirpacept
- Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaTerminatedPhase 1/2PfizerNCT05626322Written as Maplirpacept
- A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in ChinaCompletedPhase 1PfizerNCT05896774Written as Maplirpacept
- Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian CancerTerminatedPhase 1/2PfizerNCT05261490Written as maplirpacept (PF-07901801)
- A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic MalignanciesCompletedPhase 1PfizerNCT05567887Written as maplirpacept (PF-07901801)
Given in every arm · 1 — maplirpacept is usual care beside what is tested
Codes
What other systems call maplirpacept · ClinicalTrials.gg INT014794
- UNII (FDA) 44D51T6SZHMAPLIRPACEPTConfirmed FDA, Wikidata
- Wikidata Q136305678maplirpaceptConfirmed FDA, Wikidata
- NCI Thesaurus C150756MaplirpaceptOne source FDA
- DrugBank DB18441One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 44D51T6SZH | MAPLIRPACEPT | Confirmed FDA, Wikidata |
| Wikidata | Q136305678 | maplirpacept | Confirmed FDA, Wikidata |
| NCI Thesaurus | C150756 | Maplirpacept | One source FDA |
| DrugBank | DB18441 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.